Short-Term Outcomes of In-Utero Xylazine Exposure in Infants With NOWS
{{output}}
Background: Xylazine is an α2-adrenergic veterinary sedative increasingly detected as a fentanyl adulterant. Its impact on neonatal opioid withdrawal syndrome is unknown. ... ...
